References
- Fisher R I, DeVita V T, Hubbard S P, et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979; 90: 761–763
- Vinciguerra V P, Coleman M, Degnan R J. Combination chemotherapy for MOPP-resistant Hodgkin's disease (BVDS) (Abstract). Clin Res 1975; 23: 284
- Vinciguerra V P, Coleman M, Jarowski C I, et al. A new combination chemotherapy for resistant Hodgkin's disease. J Am Med Assoc 1977; 237: 33–35
- Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 1982; 96: 139–143
- Straus D J, Passe S, Koziner B, et al. Combination chemotherapy salvage of heavily pretreated patients with Hodgkin's disease: An analysis of prognostic factors in two chemotherapy trials and the literature. Cancer Treat Rep 1981; 65: 207–211
- Sutcliff S B, Wrigley P FM, Stansfeld A G, Malpas J S. Adriamy-cin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine, and prednisone (MVPP). Cancer Chemother Pharmacol 1979; 2: 209–213
- Clamon G H, Corder M P. ABVD treatment of MOPP failures in Hodgkin's disease: a re-examination of goals of salvage therapy. Cancer Treat Rep 1978; 62: 363–367
- Harker W G, Kushlan P, Rosenberg S A. Combination chemotherapy for advanced Hodgkin;s disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med 1984; 101: 440–446
- Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol 1983; 1: 432–439
- Goldman J M, Dawson A A. Combination therapy for advanced resistant Hodgkin's disease. Lancet 1975; 2: 1224–1227
- Gold J M, Dawson A A. Chemotherapy for advanced resistant Hodgkin's disease (Letter). Lancet 1981; 2: 252
- Einhorn L H, Williams S D, Stevens E E, et al. Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine. Cancer 1983; 51: 1348–1352
- Lokich J J, Frei E, Jaffe N, Tullis J. New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease. Cancer 1976; 38: 667–671
- Stutzman L, Glidewell O. Multiple chemotherapeutic agents for Hodgkin's disease. J Am Med Assoc 1973; 225: 1202–1211
- Kuentz M, Reyes F, Brun B, et al. Early responses to chemotherapy as a prognostic factor in Hodgkin's disease. Cancer 1983; 52: 780–785
- Coleman M. Chemotherapy for large-cell lymphoma: optimism and caution (Edit). Ann Intern Med 1985; 103: 140–142
- Goldie J H, Cddman A T, Gudauskas G A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
- Coleman M, Vinciguerra V P, Rafla S. Combination chemoim-munotherapy in advanced recurrent Hodgkin's disease: A randomized study of the Cancer and Leukemia Group B (Abstr). Proc Am Soc Cancer Res: Am Soc Clin Oncol 1979; 20: 428
- Santoro A, Bonadonna G, Bonfante V, Valgussa P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 1982; 306: 770–775
- Vinciguerra V P, Propert K J, Coleman M, et al. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy: A prospective randomized study by the Cancer and Leukemia Group B. J Clin Oncol 1986; 4: 838–846